Seventy-five years after its creation, the National Health Service remains one of the most powerful public institutions in the United Kingdom. Yet in the era of digital healthcare, the system appears increasingly reliant on foreign technology. A newly signed £222 million contract between four NHS trusts in Dorset and Somerset and the American software giant Epic highlights a deeper strategic question: why does the NHS continue to place its digital infrastructure in overseas hands while domestic innovation struggles to gain similar traction?
The agreement will see Somerset Foundation Trust, Dorset County Hospital Trust, University Hospitals Dorset Trust and Dorset Healthcare University Foundation Trust adopt a shared electronic patient record platform supplied by Epic, one of the largest healthcare technology companies in the United States. The ten-year contract is designed to unify data across acute, community and mental health services throughout the region. On the surface, the move reflects a familiar logic: scale, maturity and perceived reliability. Epic’s platforms already underpin some of the largest hospital systems in North America, and NHS leaders understandably want technology that can handle complex clinical environments.
But the decision also exposes a structural imbalance within Britain’s digital health economy. While the NHS increasingly recognises the importance of advanced data infrastructure, the bulk of large contracts continue to flow to a small number of global technology providers headquartered outside the United Kingdom. Domestic companies, many of which have built sophisticated clinical data platforms and artificial intelligence tools, rarely receive the same level of institutional backing. The result is a paradox: a health system that champions innovation rhetorically while often exporting its digital future.
This imbalance matters far beyond procurement policy. Healthcare data is rapidly becoming one of the most strategically valuable resources in modern economies. Electronic patient record systems sit at the centre of that ecosystem, acting as the gateway through which clinical data flows into analytics, research platforms and artificial intelligence applications. Whoever controls the architecture of those systems ultimately shapes how the data can be used, who can access it and where the economic value is generated.
When those core platforms are predominantly supplied by overseas firms, the long-term consequences ripple through the wider innovation landscape. British startups find themselves building products around infrastructure they do not control. Investors become wary of backing companies whose potential customers are structurally locked into external ecosystems. And talented engineers and entrepreneurs increasingly look abroad for markets where health systems actively support domestic technology.
The United States offers a stark contrast. Federal and state health systems have historically supported a strong domestic health technology sector, helping create companies that now dominate global markets. Epic, Cerner and other American firms grew within an environment where local procurement reinforced national capability. That ecosystem has since become self-reinforcing, producing capital, expertise and export power.
Britain, by comparison, risks becoming primarily a customer rather than a creator. The NHS remains one of the largest single-payer health systems in the world and possesses one of the richest longitudinal health datasets anywhere. Yet the infrastructure increasingly used to manage that data is designed, owned and commercially exploited elsewhere.
This is not an argument against international technology partnerships. Global collaboration is central to modern healthcare innovation, and many overseas companies provide excellent products. The question is one of balance. When domestic firms struggle to secure meaningful NHS deployments, it becomes far harder for them to mature into global competitors. Procurement decisions that appear purely operational can therefore shape the entire trajectory of a national industry.
There is also the matter of sovereignty. As healthcare systems become increasingly digitised, control over data architecture begins to resemble control over critical national infrastructure. Governments around the world are starting to recognise this reality. In sectors ranging from semiconductors to energy networks, policymakers have become more cautious about excessive reliance on foreign platforms. Healthcare data may soon fall into the same strategic category.
For the United Kingdom, the stakes are unusually high. The NHS possesses a unique combination of scale, clinical expertise and population data that should make it one of the most powerful engines of medical innovation in the world. Harnessed properly, that environment could support an entire generation of British health technology companies capable of exporting solutions globally.
Yet if procurement patterns continue to favour established international vendors almost by default, the country risks missing that opportunity. The innovation ecosystem that should surround the NHS may never fully materialise, and the economic value generated by Britain’s health data may increasingly accrue elsewhere.
The Dorset and Somerset contract is therefore more than a regional technology decision. It reflects a broader strategic choice about the future of Britain’s digital health economy. Will the NHS remain primarily a buyer of global platforms, or can it also become a catalyst for domestic innovation?
The answer will determine not only who supplies the software inside Britain’s hospitals, but who ultimately shapes the future of healthcare data itself. In an age where data, artificial intelligence and digital infrastructure are redefining medicine, the question of ownership may prove just as important as the technology itself.
